NCI-H23

NCI-H23 is a cell line derived from human lung cancer tissue. It is commonly used in biomedical research to study the biology of lung cancer and to test potential therapeutic interventions.

History[edit | edit source]

The NCI-H23 cell line was established in 1973 by the National Cancer Institute (NCI). The cells were derived from the adenocarcinoma of a 58-year-old Caucasian male. The patient had a history of heavy smoking, a common risk factor for lung cancer.

Characteristics[edit | edit source]

NCI-H23 cells are epithelial in nature and grow in a monolayer. They have a high mitotic index and are capable of forming tumors when implanted into immunodeficient mice. The cells carry several genetic mutations that are commonly found in lung cancer, including mutations in the KRAS and p53 genes.

Use in Research[edit | edit source]

NCI-H23 cells are used in a wide range of research applications. They are particularly useful for studying the molecular mechanisms of lung cancer and for testing the efficacy of potential new chemotherapeutic agents. The cells are also used in gene expression studies and in research on cancer cell metabolism.

Availability[edit | edit source]

NCI-H23 cells are available from several biological resource centers, including the American Type Culture Collection (ATCC). They are provided as a frozen stock and can be cultured in the laboratory under standard conditions.